Floatz logo

Darolutamide

Metastatic Renal Cell Carcinoma

Dana-Farber Cancer InstituteSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the Metastatic Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Inno-206
Oliver Jonas
Phase 2BB
Olaparib
Oliver Jonas
Phase 4BB
FILGRASTIM
Mayo Clinic
Phase 2BB
DEXAMETHASONE
University Hospital of Split
Phase 2BB
Zoledronate
Kelly Fitzgerald, MD
Phase 4BB

View all 50 →

Same molecule, other indications

Darolutamide is also rated in:

castration-resistant prostate carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →